Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Lowers Price Target to $56
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn has maintained an Underweight rating on Bristol-Myers Squibb (NYSE:BMY) and lowered the price target from $57 to $56.
October 11, 2023 | 1:28 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has maintained an Underweight rating on Bristol-Myers Squibb and lowered the price target from $57 to $56.
The lowered price target and maintained Underweight rating by Morgan Stanley indicates a bearish outlook for Bristol-Myers Squibb. This could potentially lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100